25.91USD-2.34%Mkt Cap: —P/E: —1d ago
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in N…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value3.42B $
Revenue (TTM)717.00M $
Gross Profit-149.00M $
Net Income (TTM)-586.00M $
Revenue/Share7.131 USD
Last Price25.91 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.4K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.36
EV/Revenue4.77
P/S—
P/B-8.52
EPS (TTM)-6.87
EPS (Forward)—
52W Range
25.0814% of range31.10
52W High31.10 USD
52W Low25.08 USD
Profitability
Gross Margin-20.78%
Oper. Margin-35.05%
EBITDA Margin-64.85%
Profit Margin-81.73%
ROE—
ROA-24.22%
Growth
Revenue Growth28.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-485.00M $
CapEx (TTM)—
FCF Margin-25.08%
FCF Yield—
Net Debt910.00M $
Net Debt/EBITDA-1.96
Balance Sheet
Debt/Equity—
Current Ratio1.73
Quick Ratio1.41
Book Value/Sh-2.9600 USD
Cash/Share2.971 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.50.58M
Float80.42M
Insiders3.44%
Institutions111.88%
Technical
SMA 5047.46 (-45.4%)
SMA 20043.02 (-39.8%)
Beta0.31
S&P 52W Chg18.16%
Avg Vol (30d)49.87K
Avg Vol (10d)203
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—